OpenAI is facing a leadership vacuum at the very core of its mission. Fidji Simo, who had only recently stepped up to lead the Artificial General Intelligence (AGI) division, is stepping down to transition into an external advisory role. This is no "strategic pivot," but rather a biological dead end. As Simo confirmed on X (formerly Twitter), a flare-up of a chronic neuroimmune disease she has lived with for seven years has made maintaining the company’s breakneck pace impossible. For a company hurtling into the future at supersonic speeds, the physical collapse of its top executives serves as a stark signal: human resources are being exhausted in the race for AGI.
The Biological Limit of the AGI Race
The crisis at OpenAI is increasingly being defined by medical diagnoses rather than aggressive poaching by competitors. Simo went on indefinite leave in April, almost immediately after her appointment as head of the AGI division. Simultaneously, CMO Kate Rouch stepped down for health reasons, and COO Brad Lightcap has effectively withdrawn from day-to-day management to focus on unspecified "special projects." The concentration of critical knowledge within a tiny circle has created a fragile structure where a single doctor’s note can derail the roadmaps of entire departments.
It’s quite haunting to spend your days building the future while fighting an incurable illness that robs you of your strength.
Simo’s reflections on the dissonance between building super-machines and physical frailty highlight a primary risk for investors: the "biological factor." When the architects responsible for turning ChatGPT into a fully autonomous agent drop out due to exhaustion, OpenAI’s technical debt is compounded by managerial paralysis. Simo’s three-month absence proved there is no viable replacement, and the hole in the executive ranks is now officially recognized as permanent.
Reorganization Under Pressure
To plug the resulting gaps, OpenAI President Greg Brockman has been forced to shoulder an overwhelming portfolio of assets. According to an internal memo cited by The Verge, following a May reorganization, Brockman is now personally overseeing product strategy and scaling across four pillars: from core infrastructure to applied sectors in healthcare and finance. While the goal is noble—to consolidate resources into a single agentic platform—in practice, it means the fate of the company’s most ambitious goals now rests on one individual. Meanwhile, business operations have been divided between CFO Sarah Friar and COO Jason Kwon.
OpenAI is attempting to build a monolithic intelligence while its own management team crumbles into fragments. Sam Altman has expressed "deep sadness," but the reality is harsher: the company’s president is now simultaneously managing data analysis, marketing, and the development of a "super-app." The aggressive push toward AGI appears to be moving faster than the biological capacity of the people tasked with inventing it. For the company’s partners, this is a wake-up call: the stability of a system dependent on the health of a handful of workaholics is rapidly approaching zero.